160 related articles for article (PubMed ID: 11087360)
1. Interaction of the antitumor compound cryptophycin-52 with tubulin.
Panda D; Ananthnarayan V; Larson G; Shih C; Jordan MA; Wilson L
Biochemistry; 2000 Nov; 39(46):14121-7. PubMed ID: 11087360
[TBL] [Abstract][Full Text] [Related]
2. Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site.
Mooberry SL; Taoka CR; Busquets L
Cancer Lett; 1996 Oct; 107(1):53-7. PubMed ID: 8913266
[TBL] [Abstract][Full Text] [Related]
3. Conformational changes in tubulin upon binding cryptophycin-52 reveal its mechanism of action.
Eren E; Watts NR; Sackett DL; Wingfield PT
J Biol Chem; 2021 Oct; 297(4):101138. PubMed ID: 34461087
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action cryptophycin. Interaction with the Vinca alkaloid domain of tubulin.
Smith CD; Zhang X
J Biol Chem; 1996 Mar; 271(11):6192-8. PubMed ID: 8626409
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends.
Panda D; DeLuca K; Williams D; Jordan MA; Wilson L
Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9313-8. PubMed ID: 9689077
[TBL] [Abstract][Full Text] [Related]
6. Interaction of cryptophycin 1 with tubulin and microtubules.
Kerksiek K; Mejillano MR; Schwartz RE; Georg GI; Himes RH
FEBS Lett; 1995 Dec; 377(1):59-61. PubMed ID: 8543019
[TBL] [Abstract][Full Text] [Related]
7. In vitro effect of cryptophycin 52 on microtubule assembly and tubulin: molecular modeling of the mechanism of action of a new antimitotic drug.
Barbier P; Gregoire C; Devred F; Sarrazin M; Peyrot V
Biochemistry; 2001 Nov; 40(45):13510-9. PubMed ID: 11695898
[TBL] [Abstract][Full Text] [Related]
8. Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1.
Bai R; Durso NA; Sackett DL; Hamel E
Biochemistry; 1999 Oct; 38(43):14302-10. PubMed ID: 10572005
[TBL] [Abstract][Full Text] [Related]
9. Localization of the antimitotic peptide and depsipeptide binding site on beta-tubulin.
Mitra A; Sept D
Biochemistry; 2004 Nov; 43(44):13955-62. PubMed ID: 15518544
[TBL] [Abstract][Full Text] [Related]
10. In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines.
Wagner MM; Paul DC; Shih C; Jordan MA; Wilson L; Williams DC
Cancer Chemother Pharmacol; 1999; 43(2):115-25. PubMed ID: 9923816
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action of the unusually potent microtubule inhibitor cryptophycin 1.
Panda D; Himes RH; Moore RE; Wilson L; Jordan MA
Biochemistry; 1997 Oct; 36(42):12948-53. PubMed ID: 9335554
[TBL] [Abstract][Full Text] [Related]
12. Binding of the epoxide cryptophycin analog, LY355703 to albumin and its effect on in vitro antiproliferative activity.
Schultz RM; Shih C; Wood PG; Harrison SD; Ehlhardt WJ
Oncol Rep; 1998; 5(5):1089-94. PubMed ID: 9683814
[TBL] [Abstract][Full Text] [Related]
13. Caulerpenyne binding to tubulin: structural modifications by a non conventional pharmacological agent.
Bourdron J; Barbier P; Allegro D; Villard C; Lafitte D; Commeiras L; Parrain JL; Peyrot V
Med Chem; 2009 Mar; 5(2):182-90. PubMed ID: 19275717
[TBL] [Abstract][Full Text] [Related]
14. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain.
Bai R; Taylor GF; Cichacz ZA; Herald CL; Kepler JA; Pettit GR; Hamel E
Biochemistry; 1995 Aug; 34(30):9714-21. PubMed ID: 7626642
[TBL] [Abstract][Full Text] [Related]
15. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
Bai RL; Pettit GR; Hamel E
J Biol Chem; 1990 Oct; 265(28):17141-9. PubMed ID: 2211617
[TBL] [Abstract][Full Text] [Related]
16. Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography.
Cruz-Monserrate Z; Mullaney JT; Harran PG; Pettit GR; Hamel E
Eur J Biochem; 2003 Sep; 270(18):3822-8. PubMed ID: 12950266
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.
Natsume T; Watanabe J; Tamaoki S; Fujio N; Miyasaka K; Kobayashi M
Jpn J Cancer Res; 2000 Jul; 91(7):737-47. PubMed ID: 10920282
[TBL] [Abstract][Full Text] [Related]
18. The thermodynamics of vinca alkaloid-induced tubulin spirals formation.
Lobert S; Ingram JW; Correia JJ
Biophys Chem; 2007 Mar; 126(1-3):50-8. PubMed ID: 16757093
[TBL] [Abstract][Full Text] [Related]
19. Interaction of tubulin with a new fluorescent analogue of vinblastine.
Chatterjee SK; Laffray J; Patel P; Ravindra R; Qin Y; Kuehne ME; Bane SL
Biochemistry; 2002 Nov; 41(47):14010-8. PubMed ID: 12437358
[TBL] [Abstract][Full Text] [Related]
20. Protein-binding patterns of the antitumor antibiotic cryptophycin 52 as measured with a two-phase partitioning system.
Kessel D
J Chromatogr B Biomed Sci Appl; 1999 Nov; 735(1):121-6. PubMed ID: 10630897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
